DE69902523D1 - Verwendung von erythropoietin zur behandlung von multiple myelom - Google Patents

Verwendung von erythropoietin zur behandlung von multiple myelom

Info

Publication number
DE69902523D1
DE69902523D1 DE69902523T DE69902523T DE69902523D1 DE 69902523 D1 DE69902523 D1 DE 69902523D1 DE 69902523 T DE69902523 T DE 69902523T DE 69902523 T DE69902523 T DE 69902523T DE 69902523 D1 DE69902523 D1 DE 69902523D1
Authority
DE
Germany
Prior art keywords
erythropoietin
multiple myeloma
treating multiple
cancer
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69902523T
Other languages
English (en)
Other versions
DE69902523T2 (de
Inventor
Nechama Haran-Ghera
Moshe Mittelman
Alpha Peled
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mor Research Applications Ltd
Yeda Research and Development Co Ltd
Original Assignee
Mor Research Applications Ltd
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mor Research Applications Ltd, Yeda Research and Development Co Ltd filed Critical Mor Research Applications Ltd
Publication of DE69902523D1 publication Critical patent/DE69902523D1/de
Application granted granted Critical
Publication of DE69902523T2 publication Critical patent/DE69902523T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69902523T 1998-04-08 1999-03-30 Verwendung von erythropoietin zur behandlung von multiple myelom Expired - Lifetime DE69902523T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL12401598A IL124015A0 (en) 1998-04-08 1998-04-08 Pharmaceutical compositions comprising a protein
PCT/IL1999/000186 WO1999052543A2 (en) 1998-04-08 1999-03-30 Pharmaceutical compositions comprising erythropoietin for treatment of cancer

Publications (2)

Publication Number Publication Date
DE69902523D1 true DE69902523D1 (de) 2002-09-19
DE69902523T2 DE69902523T2 (de) 2003-04-24

Family

ID=11071408

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69902523T Expired - Lifetime DE69902523T2 (de) 1998-04-08 1999-03-30 Verwendung von erythropoietin zur behandlung von multiple myelom

Country Status (11)

Country Link
US (2) US6579525B1 (de)
EP (1) EP1067955B1 (de)
JP (1) JP4456271B2 (de)
AT (1) ATE222119T1 (de)
AU (1) AU3052799A (de)
CA (1) CA2366674C (de)
DE (1) DE69902523T2 (de)
ES (1) ES2185323T3 (de)
HK (1) HK1033910A1 (de)
IL (2) IL124015A0 (de)
WO (1) WO1999052543A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5462501A (en) * 2000-05-02 2001-11-12 Action Pharmaceuticals Aps Use of alpha-msh and epo for preventing or treating ischemic conditions
DE10219545A1 (de) * 2002-04-26 2003-11-06 Lang Florian Regulation der Apoptose
PL2295056T3 (pl) * 2004-03-15 2016-07-29 Sunesis Pharmaceuticals Inc Zastosowanie SNS-595 do leczenia białaczki
US7588745B2 (en) * 2004-04-13 2009-09-15 Si Options, Llc Silicon-containing products
WO2006006165A2 (en) * 2004-07-12 2006-01-19 Yeda Research And Development Co. Ltd. Use of erythropoietin for enhancing immune responses and for treatment of lymphoproliferative disorders
US8580814B2 (en) * 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
CA2654876A1 (en) * 2006-06-12 2007-12-21 Sunesis Pharmaceuticals, Inc. 1-8-naphthyridine compounds for the treatment of cancer
KR20180041269A (ko) 2008-01-22 2018-04-23 아라임 파마슈티칼즈, 인크. 조직 손상 관련 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체
CA2712606A1 (en) 2008-02-08 2009-08-13 Ambrx, Inc. Modified leptin polypeptides and their uses
BRPI0916515B8 (pt) 2008-07-23 2021-07-27 Ambrx Inc polipeptídeo de fator estimulante de colônias de granulócitos bovino (bg-csf), formulação farmacêutica e composição compreendendo o mesmo
UA106731C2 (uk) 2008-09-26 2014-10-10 Амбркс, Інк. Модифіковані поліпептиди еритропоетину тварин та їх застосування
EA200900517A1 (ru) * 2009-04-01 2010-08-30 Общество С Ограниченной Ответственностью "Лэнс-Фарм" Применение эритропоэтина для лечения миелобластного лейкоза
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
KR20160052537A (ko) * 2013-07-17 2016-05-12 아라임 파마슈티칼즈, 인크. 조직 손상과 연관된 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체
WO2015189813A1 (en) 2014-06-12 2015-12-17 Andremacon S.R.L. Use of negative functional modulators of erythropoietin for therapy
PL230756B1 (pl) * 2015-09-11 2018-12-31 Univ Medyczny W Bialymstoku Erytropoetyna oraz inhibitor kinazy Brutona w postaci 2- cyjan o-N-( 2,5-dibromofenylo)- 3-hydroksy-2- butenamidu do zastosowania jako lek oraz ich zastosowanie do wytwarzania leku do terapii nowotworu
CN106075447B (zh) * 2016-06-24 2018-07-10 中国人民解放军第二军医大学 一种epo受体及其在伴红细胞增多症的肝细胞癌中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100263845B1 (ko) 1989-10-13 2000-08-16 스튜어트 엘.왓트 에리트로포이에틴 동형체와 그의 제조방법 및 그를 포함하는제약학적 조성물
US6012450A (en) * 1993-01-29 2000-01-11 Aradigm Corporation Intrapulmonary delivery of hematopoietic drug
US20020052309A1 (en) 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury

Also Published As

Publication number Publication date
JP2002511419A (ja) 2002-04-16
EP1067955B1 (de) 2002-08-14
US20030216316A1 (en) 2003-11-20
US6579525B1 (en) 2003-06-17
IL138705A (en) 2007-02-11
AU3052799A (en) 1999-11-01
JP4456271B2 (ja) 2010-04-28
ES2185323T3 (es) 2003-04-16
WO1999052543A3 (en) 1999-12-16
IL124015A0 (en) 1999-01-26
CA2366674C (en) 2010-12-21
WO1999052543A2 (en) 1999-10-21
EP1067955A2 (de) 2001-01-17
HK1033910A1 (en) 2001-10-05
CA2366674A1 (en) 1999-10-21
ATE222119T1 (de) 2002-08-15
DE69902523T2 (de) 2003-04-24

Similar Documents

Publication Publication Date Title
DE69902523D1 (de) Verwendung von erythropoietin zur behandlung von multiple myelom
DE59903921D1 (de) Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen
EA199800391A1 (ru) Ингибирование роста опухоли антисмысловыми олигонуклеотидами к il-8 и il-8 рецептору
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
ATE440618T1 (de) Kombination von cpg und antikírpern gegen cd19, cd20,cd22 oder cd40 zur prävention oder behandlung von krebs.
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
RU94031102A (ru) Сульфамиды в качестве антагонистов эндотелина и способ лечения соответствующих заболеваний
ATE230607T1 (de) Verwendung von neurturin protein zur vorbeugung und behandlung von gehörverlust
ATE411016T1 (de) Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
DE69911210D1 (de) Verwendung von piperin und derivate davon zur behandlung von hautpigmentierungstörungen und hautkrebs
WO2003103581A3 (en) COMPOSITIONS AND METHODS FOR LIVER GROWTH AND PROTECTION
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
ATE271873T1 (de) Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
DE60123138D1 (de) Verwendung von progesteronrezeptorhemmern zur behandlung von steroid-resistentem brustkrebs
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
DE59900286D1 (de) Verwendung von sphingosin-1-phosphat, sphingosin-1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
DE60106604D1 (de) Verwendung von aloe-emodin zur behandlung von neuroektodermalen tumoren
ATE369143T1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
ATE365718T1 (de) Substituierte 11-phenyl-dibenzazepin-verbindungen,die nützlich sind zur behandlung oder vorbeugung von durch abnormale zellproliferation gekennzeichneten krankheiten
DE59911556D1 (de) Arzneimittel zur vermeidung oder behandlung von papillomavirus-spezifischem tumor
DE59904564D1 (de) Verwendung von acetylcholinesterase-inhibitoren zur behandlung von delirien
ATE291434T1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition